Trials / Completed
CompletedNCT03342573
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris: A Single Arm, Open-label Exploratory Trial
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the potential effectiveness of Cosentyx in the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cosentyx | Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks. |
Timeline
- Start date
- 2018-04-01
- Primary completion
- 2022-01-01
- Completion
- 2022-02-01
- First posted
- 2017-11-17
- Last updated
- 2022-02-24
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03342573. Inclusion in this directory is not an endorsement.